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Transport of macromolecules through the nuclear pore by importins and exportins plays a
critical role in the spatial regulation of protein activity. How cancer cells co-opt this process to
promote tumorigenesis remains unclear. The epidermal growth factor receptor (EGFR) plays
a critical role in normal development and in human cancer. Here we describe a mechanism of
EGFR regulation through the importin β family member RAN-binding protein 6 (RanBP6), a
protein of hitherto unknown functions. We show that RanBP6 silencing impairs nuclear
translocation of signal transducer and activator of transcription 3 (STAT3), reduces STAT3
binding to the EGFR promoter, results in transcriptional derepression of EGFR, and increased
EGFR pathway output. Focal deletions of the RanBP6 locus on chromosome 9p were found in
a subset of glioblastoma (GBM) and silencing of RanBP6 promoted glioma growth in vivo.
Our results provide an example of EGFR deregulation in cancer through silencing of com-
ponents of the nuclear import pathway.
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The epidermal growth factor receptor (EGFR) is a trans-membrane receptor of the ErbB tyrosine kinase family thatplays a central role in cell differentiation, proliferation, and
survival1. EGFR binding to its ligands, e.g., the epidermal growth
factor (EGF), leads to phosphorylation and dimerization of the
receptor, recruitment of proteins containing Src homology 2
(SH2), and phosphotyrosine-binding (PTB) domains, and acti-
vation of multiple downstream signaling pathways, including the
mitogen-activated protein kinase (MAPK) pathway, the phos-
phatidylinositol 3-kinase (PI3K) pathway, and the phospholipase
C-γ (PLC-γ) pathway. Activation of EGFR is followed by a series
of molecular events that contain EGFR signal strength and
duration. These events include endocytosis of the ligand-bound
receptor, ubiquitination, and lysosomal degradation of the
receptor–ligand complex, and dephosphorylation of the receptor
protein by protein tyrosine phosphatases2.
Recent studies have challenged the traditional view of EGFR
regulation. Structural studies have characterized a distinctive
“receptor-mediated” dimerization mechanism and identified
allosteric changes that govern the regulation of the intracellular
kinase domain3. The study of EGFR and its coreceptors at the
systems level identified additional EGFR-binding partners,
dynamic patterns of pathway activation, and further layers of
EGFR regulation through feedback inhibitors and intracellular
signal compartmentalization4–6. Together, these findings high-
light the need for a deeper understanding of EGFR regulation
through other signaling pathways.
To identify further mechanisms of EGFR regulation, we
characterized the EGFR “interactome” through EGFR immu-
noaffinity purification and identified Ran-binding protein 6
(RanBP6) as EGFR-associated protein. RanBP6 silencing resulted
in increased EGFR RNA and protein levels and augmented EGFR
pathway activation in response to EGF. Focal and broad deletions
including the RANBP6 gene locus were identified in glioblastoma
(GBM) and RanBP6 silencing accelerated glioma growth in vivo.
Taken together, these findings suggest that RanBP6 serves as
EGFR regulator that is disrupted in human cancer.
Results
RanBP6 interacts with EGFR and Ran-GTPase pathway
members. To further advance our understanding of EGFR reg-
ulation, we immunoprecipitated endogenous EGFR from whole-
cell extracts of A431 human cancer cells, which had been serum
starved overnight and then stimulated for 5 min with EGF, and
subjected trypsin digests of EGFR-associated proteins to liquid
chromatography-tandem mass spectrometry (LC-MS/MS). We
identified 431 EGFR-associated proteins in three independent
biological replicates. This list of proteins (Supplementary Data 1)
comprised the majority of proteins (117/183) detected in a prior
examination of the EGFR interactome in A431 cells7. About 40%
of the proteins (175/431) associating with EGFR were listed as
EGFR interactors in the Biological General Repository for Inter-
action Datasets (BioGRID) and represented well-characterized
members of the canonical EGFR pathway, including components
of the adaptor protein complex 2 (AP-2), members of the CBL
family of E3 ubiquitin-protein ligases, growth factor receptor-
bound protein 2 (GRB2), SHC-transforming protein 1 (SHC1),
son of sevenless homolog 1 (SOS1), the phosphatidylinositol 4,5-
bisphosphate 3-kinase catalytic subunit α and β isoforms
(PIK3CA and PIK3CB, respectively), phosphatidylinositol 3-
kinase regulatory subunit α (PIK3R1), 1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase gamma-1 (PLCG1), and ERBB
receptor feedback inhibitor 1 (ERRFI; also known as mitogen-
inducible gene 6 protein).
In addition to these proteins with well-documented roles in
EGFR signaling, gene ontology analysis (www.geneontology.org)
showed an enrichment of proteins involved in protein import
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Fig. 1 Importin β-like protein RanBP6 interacts with EGFR. a Left panel, schematic representation of EGFR immunoaffinity purification and LC-MS/MS
analysis in A431. Right panel, plot showing the ten top categories of the gene ontology enrichment analysis of the EGFR-associated proteins. b List of the
unique peptides for RanBP6 identified in the MS analysis and the replicate in which the peptide was identified are indicated in the table. c Co-
immunoprecipitation of EGFR and V5 epitope-tagged RanBP6-V5 in A431 cells. Top panel, IP using V5 antibody; bottom panel, immunoblot of whole-cell
lysates (WCL). d Conserved domains within the family of importin β-related proteins. RanBP6 includes an importin β-like N-terminal domain (Imp. N-ter),
seven HEAT repeats, and a putative Ran-binding domain (RBD). The number to the right of each protein shows the total number of amino acids. e RanBP6
interacts with nuclear but not cytoplasmic Ran-GTPase. Subcellular fractionation of HEK-293T cells (right panel) shows that Ran is present in both nuclear
and cytoplasmic compartments, but only interacts with RanBP6 in the nuclear fraction (left panel). f Venn diagram representing overlapping proteins
between the RanBP6-V5 and the EGFR immunoaffinity purifications. See Supplementary Data 5. g GST pulldown assay confirms the interaction of RanBP6
with importin-α1, importin-β1, RanGAP1, and nuclear pore complex 93 (NUP93) in HEK-293T whole-cell lysates
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into nucleus (Fig. 1a; Supplementary Data 2). The most highly
enriched pathway (GO: 0006610) included importin subunit β-1,
importin-5, transportin-2, importin-4, 60s ribosomal protein L23,
transportin-1, and RanBP6. Within this group of proteins, only
RanBP6 had not previously been reported to bind to EGFR or
functionally characterized. We therefore selected it for further
study. RanBP6 was identified through eight different unique
peptides (Fig. 1b). We cloned a doxycycline (Dox)-inducible
RanBP6-V5-tagged complimentary DNA (cDNA) construct and
expressed it in A431 cells. Immunoprecipitation with an antibody
directed against the V5 epitope confirmed the interaction between
RanBP6 and EGFR (Fig. 1c). We also examined the interaction
between RanBP6 and EGFR in cells that do not overexpress
EGFR. In both (HEK)-293T and LN18 GBM cells, immunopre-
cipitation of endogenous EGFR pulled down RanBP6 (Supple-
mentary Fig. 1).
RanBP6 contains a putative importin N-terminal domain (Imp.
N-ter) (Fig. 1d), suggesting that it is a member of the importin β
superfamily8. By sequence similarity with RanBP5, which
mediates nuclear import of ribosomal proteins9, RanBP6 also
contains several HEAT (huntingtin, elongation factor 3, the
PR65/A subunit of protein phosphatase 2A, and the lipid kinase
Tor) repeats and a putative ran-binding domain (RBD). Sequence
alignment of the putative RBDs of RanBP6, RanBP5, and
importin β1 showed a high sequence homology across different
species (Supplementary Fig. 2). We therefore examined interac-
tions of RanBP6 with other members of the Ran-GTPase
pathway. Classic nuclear shuttling is mediated by an importin-
α∙β complex where importin α recognizes a cargo protein
containing a nuclear localization signal and these two proteins
then form a ternary complex with importin β1. The ternary
complex is dissociated in the nucleus and cargo protein released
after binding of importin β1 to nuclear Ran-GTP10. Importin-β
and β-like importins can mediate nuclear translocation without
the assistance of importin-α11,12. We therefore examined the
association of RanBP6 with several members of the RanGTPase-
mediated nuclear transport pathway. Pulldown assays of GST-
bound RanBP6 with nuclear and cytoplasmic fractions of HEK-
293T cells showed that RanBP6 bound Ran only in the nuclear
fraction, where Ran is predominantly GTP-bound. We also
observed an interaction between RanBP6 and RCC1, a guanine
nucleotide exchange factor that mediates the conversion of
RanGDP to RanGTP in the nucleus (Fig. 1e).
To gain a broader view of proteins that interacted with
RanBP6, we affinity-purified RanBP6 from A431 cells expressing
a Dox-inducible RanBP6-V5 construct and performed LC-MS/
MS analysis of four independent experiments. We observed
interactions of RanBP6 with 232 proteins, including EGFR
(Supplementary Data 3). This list of proteins was highly enriched
for gene ontology pathways related to protein targeting to
membranes (Supplementary Data 4). A considerable subset of
proteins which associated with EGFR in our prior analysis of the
EGFR interactome (84/431) also associated with RanBP6 (Fig. 1f;
Supplementary Data 5). Interestingly, this list of proteins did not
include any of the canonical EGFR pathway members, but did
include nuclear pore complex protein Nup93 and multiple
components of the SEC61 protein complex (Sec61α1, signal
sequence receptor subunit α and δ), which facilitates movement
of EGFR between the cytoplasm and the endoplasmic reticulum
(ER) in the process of routing the receptor toward the nucleus13–
15. Using GST-RanBP6 fusion protein as bait, we confirmed in
whole-cell lysates the interaction between RanBP6 and nuclear
pore complex 93 (Nup93), importin subunit α-1 (importin α1),






























































































































































































Fig. 2 RanBP6 regulates EGFR levels and EGFR signal output. a RanBP6 knockdown (KD) raises EGFR protein levels in HEK-293T cells. Dox doxycycline. b
RanBP6 KD increases EGFR mRNA levels in HEK-293T cells. Shown are RT-qPCR results. c CRISPR/Cas9-mediated knockout of RanBP6 increases EGFR
mRNA (left panel) and EGFR protein (right panel) levels in HEK-293T cells. d RanBP6 KD increases transcription of a luciferase reporter gene from EGFR
promoter, but not from the β-actin (ACTB) promoter, in HEK-293T. e RanBP6 KD increases activation of the EGFR downstream signaling pathways and
does not impair EGF-induced EGFR degradation in HEK-293T cells. Upper panel, immunoblot of whole-cell lysates serum starved for 16 h and then
stimulated with EGF (100 ng/ml) for the indicated time points; Lower panel, densitometric analysis of EGFR. Data in bar graphs are represented as mean±
SD (n≥ 3). Student’s t test: ***p< 0.001; **p< 0.01; ns not significant
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protein RanGAP1, a GTPase-activating protein, which hydrolyzes
RanGTP into RanGDP in the cytoplasm (Fig. 1g). Taken together,
our experiments identify RanBP6 as EGFR-interacting protein
and member of the Ran-GTPase nuclear transport pathway.
RanBP6 represses EGFR transcription and EGFR signal out-
put. Several proteins that bind EGFR, such as CBL family mem-
bers or ERBB receptor feedback inhibitor 1, play critical roles in
EGFR regulation4–6. To determine whether RanBP6 might play a
role in regulating EGFR levels or function, we generated HEK-
293T sublines expressing two different Dox-inducible RanBP6-
short hairpin RNAs (shRNAs). RanBP6 knockdown with either
hairpin increased EGFR protein levels (Fig. 2a).
We next evaluated the effects of RanBP6 on EGFR mRNA
levels. Dox-induced knockdown of RanBP6 raised EGFR mRNA
levels, typically about two-fold (Fig. 2b). Complete RanBP6
depletion using the Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR)/Cas9 system resulted in a more
pronounced elevation of EGFR mRNA and protein levels (Fig. 2c).
RanBP6 knockdown also increased the expression of a luciferase
reporter cloned downstream of the EGFR promoter sequence, but
had no effect on a control β-actin luciferase reporter (Fig. 2d),
suggesting that RanBP6 regulates EGFR RNA levels through
effects on EGFR promoter activity.
Lastly, we examined whether the increase in EGFR levels
associated with RanBP6 depletion resulted in increased EGFR
pathway output. This was indeed the case, as demonstrated by
increased phosphorylation of EGFR, the adapter protein Gab1,
and downstream EGFR pathway members ERK1/2, Akt, and S6
kinase following EGF induction (Fig. 2e). Of note, the rate of
EGF-induced EGFR protein degradation was comparable in the
absence and presence of Dox, further supporting the conclusion
that increased EGFR protein levels in RanBP6 knockdown cells
were not the result of impaired EGFR protein degradation.
RanBP6 promotes nuclear translocation of STAT3. Members of
the β-importin-like protein superfamily transport a variety of
cargoes, including transcription factors. We hypothesized that
RanBP6 might facilitate the nuclear transport of a transcription
factor that regulates EGFR promoter activity. We therefore
examined the subcellular localization of several transcription
factors. We included the transcription factor STAT3 in our
analysis because it associated with EGFR in our mass spectro-
metric analysis (Supplementary Data 1), had previously been
shown to associate with EGFR16–18, and has been proposed to
enter the nucleus through an importin-mediated transport
mechanism19. RanBP6 knockout cells showed decreased nuclear
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Fig. 3 RanBP6 promotes nuclear translocation of STAT3. a RanBP6 knockout (KO) increases cytoplasmic STAT3 and lowers nuclear STAT3. Left panel,
immunoblots of cytoplasmic (Cyt.) and nuclear (Nuc.) cell fractions; right panel, densitometry of STAT3 immunoblots. b RanBP6 KD impairs IL-6-induced
nuclear STAT3 translocation. Left panel, confocal immunofluorescence. RFP is used as a reporter for shRNA expression. Right panel, ratios of nuclear/
cytoplasmic STAT3 staining (field of views: vehicle, n= 18; ruxolitinib, n= 13; RANBP6-shRNA, n= 21). The janus kinase (JAK) inhibitor ruxolitinib was
included as a positive control. Scale bar= 10 μm. c RanBP6 KD decreases transcription of STAT3 reporter gene. SIE sis-inducible elements. d Gene
expression profiling showing the effect of RanBP6 KD on endogenous STAT3 target genes. Heatmap represents the enrichment scores from single-sample
gene set enrichment analysis (ssGSEA) of three biological replicates. Student’s t test p-values (Dox− vs. Dox+) for each gene sets are indicated. e
Quantitative PCR analysis of the expression of some RanBP6-regulated genes selected from ssGSEA (top panel) confirmed to be regulated by STAT3
(bottom panel). Data are represented as mean± SD (n≥ 3). Student’s t test: ***p< 0.001; **p< 0.01; ns not significant
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observed no changes in the subcellular localization of several
other cancer-related proteins, including the transcription factors
p53 and c-Jun, retinoblastoma-associated protein (RB), p27Kip1,
forkhead box protein O3 (FOXO3), and survivin (Fig. 3a; Sup-
plementary Fig. 3). We also examined the effects of RanBP6 on
nuclear translocation of STAT3 by immunofluorescence. RanBP6
knockdown impaired interleukin 6-induced nuclear translocation
of STAT3, similar to the ATP-competitive janus kinases (JAK)
inhibitor ruxolitinib (Fig. 3b; Supplementary Fig. 4).
We next examined the effect of RanBP6 on STAT3-regulated
gene expression. We observed reduced expression of an engineered
STAT3 reporter gene following RanBP6 knockdown (Fig. 3c). To
evaluate the effects of RanBP6 on the expression of endogenous
STAT3 target genes, we used Affymetrix gene expression arrays and
single-sample gene set enrichment analysis (ssGSEA). Gene sets
that have been reported to be activated by STAT3 (MsigDB, http://
www.broadinstitute.org/gsea/msigdb/) showed lower enrichment
scores in RanBP6 knockdown cells, whereas gene sets that are
negatively regulated by STAT3 (Dauer-STAT3-targets-DN) showed
higher enrichment scores in RanBP6 knockdown cells (Fig. 3d). We
confirmed these results by quantitative PCR for several of the genes
that have been reported to be activated (PTGS2, MAFF, and
EFNB2) or repressed (IFIT1 and CPS1) by STAT3. These genes
showed similar changes in expression following RanBP6 and
STAT3 knockdown, respectively (Fig. 3e).
RanBP6 represses EGFR transcription through STAT3. Given
our findings that RanBP6 regulates nuclear translocation of
STAT3 and STAT3-dependent transcription, we wondered whe-
ther RanBP6 might mediate transcriptional repression of EGFR
through STAT3. We first examined the effect of STAT3 knock-
down on EGFR mRNA levels using a doxycyline-inducible
shRNA construct and observed increased EGFR mRNA and
protein levels following STAT3 knockdown (Fig. 4a). We next
examined whether EGFR might be a direct target of transcrip-
tional repression by STAT3. Using the Jaspar transcription profile
database (http://jaspar.genereg.net)20, we identified multiple
putative STAT3-binding sites in a 1.5 kb region upstream to the
transcription starting site (TSS) of the EGFR gene (Supplemen-
tary Table 1). We selected two regions, a proximal and a distal
(EGFR_1, −1340:−1111; EGFR_2, −223:−117), for further analy-
sis. By performing an anti-STAT3 ChIP assay, we found that
STAT3 protein is recruited to these two specific regions and that
the binding is lost upon RanBP6 silencing (Fig. 4b). Similar
binding was observed for PTGS2, a known STAT3 target gene,
but not for the negative control HPRT.
Since RanBP6 is associated with both STAT3 and phosphory-
lated STAT3 (tyrosine 705) (Fig. 4c), we explored whether
transcriptional repression of EGFR might be mediated by
activated STAT3. Expression of a STAT3 mutant with constitu-
tive nuclear localization (STAT3C) was sufficient to lower EGFR
mRNA levels (Fig. 4d), whereas inhibition of STAT3 phosphor-
ylation with the JAK kinase inhibitor ruxolitinib raised EGFR
levels (Fig. 4e). Of note, RanBP6 silencing lost its ability to raise
EGFR levels in the setting of sustained (12 h) pharmacological
p-STAT3 blockade by ruxolitinib (Fig. 4f, compare EGFR ratios
lane 6:lane 5 vs. lane 2:lane 1), suggesting that RanBP6 represses
EGFR transcription through activated STAT3.
We also explored a potential contribution of exportin-1
(XPO1/CRM1) in this process because XPO1 associated with
RanBP6 and EGFR in our mass spectrometric analyses (Supple-
mentary Data 5) and CRM1 inhibition had been reported to
reduce STAT3 levels in a breast cancer cell line21. However, we
observed no effects of CRM1 inhibition on RanBP6 or the levels
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Fig. 4 STAT3 represses EGFR transcription. a STAT3 KD raises EGFR mRNA (left panel) and EGFR protein levels (right panel) in HEK-293T. b STAT3
binding to the EGFR promoter is impaired by RanBP6 KD. Bottom panel, ChIP experiments on the promoter of indicated genes with STAT3 antibody in LN18
cells with Dox-inducible shRanBP6. Plotted values are relative enrichments to % input, measured for two regions (EGFR_1 and EGFR_2) in 1.5 kb upstream
of EGFR transcriptional start site (TSS) (see top panel). Binding to the PTGS2 and HPRT promoter was used as positive and negative control, respectively. c
STAT3 and p-STAT3 (Y-705) bind GST-RanBP6 fusion protein in HEK-293T whole-cell lysates. d Expression of a constitutive active STAT3 mutant
decreases EGFR mRNA (left panel) and EGFR protein levels (right panel) in HEK-293T. e Inhibition of STAT3 activation by JAK kinase inhibitor ruxolitinib
raised EGFR protein level in HEK293T. f JAK-STAT blockage with ruxolitinib mitigates the effect of RanBP6 KD on EGFR protein levels in HEK-293T. Right
panel, densitometric analysis of EGFR ratio between Dox+ and Dox− samples for each treatment. Data in bar graphs are represented as mean± SD (n≥ 3).
Student’s t test: ***p< 0.001; **p< 0.01; ns not significant
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EGFR regulation by RanBP6 is disrupted in PTEN-deficient
cells. In our initial characterization of the interaction between
EGFR and RanBP6 in A431 cells, we noted that EGF stimulation
(5 min, 100 ng/ml) reduced the interaction between RanBP6 and
EGFR (Fig. 5a). This suggested that RanBP6 might be part on an
auto-regulatory mechanism where suppression of EGFR tran-
scription by RanBP6 is temporarily inactivated following EGFR
activation, perhaps to allow restoration of EGFR protein levels
following ligand-induced receptor degradation. Similar to our
observation in A431 cells, EGF reduced the association between
RanBP6 and EGFR in HEK-293T cells. The effect of EGF on the
RanBP6–EGFR association could be rescued by pretreatment of
cells with the AKT kinase inhibitor MK-2206 (Fig. 5b).
We next examined the effect of the phosphatase and tensin
homolog (PTEN), a negative regulator of the PI3K signaling
pathway, on the interaction between EGFR and RanBP6. GST-
tagged RanBP6 associated with endogeneous EGFR in lysates
from mouse embryonic fibroblasts (MEFs) but not Pten
knockout MEFs (Fig. 5c). Loss of Pten not only impaired the
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Fig. 5 EGFR regulation by RanBP6 is disrupted in PTEN-deficient cells. a Co-immunoprecipitation of EGFR and V5 epitope-tagged RanBP6-V5 in A431 cells serum
starved and induced with EGF (100 ng/ml) for 5min. Top panel, IP using V5 antibody; bottom panel, immunoblot of whole-cell lysates (WCL). b Interaction of
GST-RanBP6 fusion protein with EGFR is Akt dependent. Left panel, GST pulldown; right lower panel, densitometric quantification of GST pulldown; right upper
panel, immunoblot of whole-cell lysate. c PTEN loss disrupts interaction of GST-RanBP6 fusion protein with EGFR. Left panel, GST-RanBP6 fusion protein interacts
with EGFR in Ptenlox/lox but not PtenΔ/Δ MEFs; Right panel, immunoblot of whole-cell lysates. d RanBP6 KD raises Egfr mRNA level in Ptenlox/lox but not PtenΔ/Δ
MEFs. Left panel, Egfr mRNA level; middle panel, Ranbp6 mRNA level; right panel, Pten mRNA level. e Left panel, negative correlation between RANBP6 and EGFR
mRNA Z-score in the Cancer Cell Line Encyclopedia (n= 877, Pearson product–moment correlation r= −0.203, p-value= 1e−09). Right panels, cancer cell lines
were stratified accordingly to PTEN status. Inverse correlation between RANBP6 and EGFR mRNA levels only in PTEN-intact cancer cell lines (n= 734,
Pearson product–moment correlation r= −0.22, p-value= 2e−09) but not PTEN altered cell lines (n= 143, Pearson product–moment correlation r= −0.066,
p-value=0.43). Data in bar graphs are represented as mean± SD (n≥ 3). Student’s t test: ***p<0.001; ns not significant
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effects of RanBP6 knockdown on Egfr mRNA levels (Fig. 5d),
demonstrating that both RanBP6 functions are PTEN-dependent.
Since PTEN is commonly silenced in cancer22, we wondered
whether PTEN status might affect the relationship between EGFR
and RANBP6 RNA levels in human cancer cell lines. We
examined this question across a panel of 877 genetically
annotated human cancer cell lines included in the publically
available Cancer Cell Line Encyclopedia (CCLE)23. Consistent
with our findings in isogenic models, we observed an inverse
relationship between RANBP6 and EGFR mRNA levels (Fig. 5e,
left panel). When cell lines were stratified by PTEN status, the
inverse correlation between RANBP6 and EGFRmRNA levels was
only present in cancer cell lines without PTEN alteration
(Pearson product–moment correlation r = −0.22, p-value = 2e
−09) but not in cell lines with PTEN alteration (Pearson
product–moment correlation r = −0.066, p-value = 0.43) (Fig. 5e,
right panels) (Supplementary Data 6). Taken together, our
findings suggest that EGFR regulation by RanBP6 is disrupted
in the setting of acute (e.g., EGF stimulation) or sustained (e.g.,
PTEN loss) PI3K pathway activation. Our observation that
RanBP6 functions are dependent of the activation state of the
PI3K pathway is reminiscent of the observation that PI3K
pathway activity regulates the function of RanBP324. Unlike
RanBP3, however, RanBP6 does not appear to be the recipient of
an AKT-regulated phosphorylation signal since EGFR from
lysates of PTEN-deficient cells also failed to bind bacterially
purified GST-RanBP6 fusion protein, which is not amenable to
posttranslational modification.
RanBP6 shows tumor suppressor-like activity in glioblastoma.
Aberrant activation of EGFR in human cancer typically occurs
through alterations in the EGFR gene, but can also be the result of
defects in physiologic EGFR feedback regulation25. We therefore
examined whether RanBP6 exhibits tumor suppressor-like
activity. We examined this question in experimental models of
GBM because we had observed in several GBMs focal deletions of


















































































































































Homdel Hetloss Diploid Gain
RANBP6 Copy number (GISTIC)































Fig. 6 RanBP6 suppresses growth factor output and glioma growth. a Focal deletions of the RANBP6 (left) and CDKN2A (right) loci in GBM. b Relationship
between RANBP6 copy number and mRNA levels in GBM (n= 151); Tukey’s honest significant difference: ***p< 0.001. c RanBP6 protein levels in a panel of
established patient-derived GBM tumor spheres. The immunoblots of whole-cell lysates are shown. d Ectopic expression of RanBP6-V5 in RanBP6-low
TS516 GBM neurosphere reduces anchorage-independent growth. e Ectopic expression of RanBP6-V5 reduces EGFR protein levels in a time-dependent
manner. f RanBP6 overexpression reduces tumor growth (left panel) and EGFR expression in a TS516 xenograft model (right panel). Student’s t test:
*p< 0.05. g RanBP6 KD reduces survival in RCAS-tva mouse glioma model. Kaplan–Meier survival curves of PDGFB-induced gliomas generated in
Nestin-tva mice injected with either RCAS-RanBP6 shRNA or RCAS-Luciferase shRNA as a control. h Tumor grade (WHO classification) of gliomas in the
RCAS-tva model. i RanBP6 KD increases Egfr mRNA in samples from the RCAS-tva mice. Data in bar graphs are represented as mean± SD (n≥ 3)
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deletions occurred independently of deletions in CDKN2A
(Fig. 6a), suggesting that they represented two independent events
with selective pressure for the loss of each gene independently.
Overall, ~40% of GBMs in the TCGA data sets showed loss of at
least one RANBP6 allele. Copy loss at the RANBP6 gene locus was
most common in the “classical” GBM subgroup (Supplementary
Fig. 6), which has been linked to deregulated EGFR activation26.
Copy loss at the RANBP6 gene locus was correlated with reduced
RANBP6 mRNA levels (Fig. 6b; Supplementary Data 7). RANBP6
was lower in tumor tissue compared to non-tumoral brain tissue
(Supplementary Fig. 7).
We next examined the relationship between RanBP6 and
EGFR expression in GBM. In human GBM tumor sections, we
observed an inverse correlation between RanBP6 and EGFR
protein levels (Supplementary Fig. 8) and RanBP6 knockdown
upregulated EGFR expression in the human GBM cell line LN18
(Supplementary Fig. 9), consistent with earlier results in HEK-
293T cells and MEFs.
Western blotting of five patient-derived GBM tumor spheres
showed markedly decreased RanBP6 protein levels in one of the
five tumor sphere lines (TS516 cells) (Fig. 6c). We stably
transduced TS516 cells with a Dox-inducible RanBP6-V5
construct and observed a reduction in soft agar colony formation
and reduced EGFR protein levels upon Dox treatment (Fig. 6d, e).
Induction of RanBP6-V5 also reduced tumor growth and EGFR
expression in subcutaneous TS516 xenografts (Fig. 6f). RanBP6
reconstitution similarly reduced soft agar growth in RanBP6-low
SF268 GBM cells (Supplementary Fig. 10).
Lastly, we examined the effect of RanBP6 silencing on in vivo
glioma growth using the RCAS-tva mouse glioma model. The
RCAS-tva system utilizes an avian leukosis virus-based vectors
(RCAS) to mediate gene transfer into cells specifically expressing
the tv-a receptor27. We injected newborn N-tva mice, that express
the Tv-a under the control of the Nestin promoter, a well-known
marker of neural stem and progenitor cells, with cells producing
the RCAS retroviruses carrying the platelet-derived growth
factor-B (PDGFB) in combination with either a mouse
RanBP6 shRNA or an shRNA for luciferase as control. RanBP6
knockdown decreased survival, with mice injected with the
RanBP6 shRNA living an average of 189 days (n = 10) and control
mice living 275.5 days (n = 14) (p = 0.047, log-rank test) (Fig. 6g)
and promoted the development of higher-grade gliomas (Fig. 6h;
Supplementary Fig. 11). Cells derived from RanBP6 knockdown
tumors showed increased Egfr mRNA levels (Fig. 6i).
Discussion
Our study introduces RanBP6, a protein with currently unknown
functions, as member of the importin β superfamily and EGFR
regulator. EGFR continuously cycles between the plasma mem-
brane and the endosomal compartment. Activation of EGFR is


































Fig. 7 EGFR regulation by RanBP6 (model). A (small) pool of EGF receptors functions as a scaffold for RanBP6-mediated nuclear import of STAT3. Nuclear
STAT3 represses EGFR transcription. The solid lines between EGFR–STAT3–RanBP6 and RanBP6–Ran indicate protein–protein interactions (i.e., not
necessarily direct molecular interactions). This mechanism of EGFR regulation serves to repress EGFR transcription at steady state and is inactivated when
the cellular demand for EGFR transcription increases (e.g., following EGF-induced receptor protein degradation). Cancer cells inactivate this physiologic
mechanism of EGFR regulation through deletion of the RANBP6 gene or silencing of PTEN (which disrupts the EGFR–RanBP6 interactions)
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strength and duration. In parallel, EGFR signaling is reinforced
through the induction of autocrine ligands, which are unable to
induce EGFR downregulation and through an increase in EGFR
mRNA levels28–30. These positive feedback mechanisms aim to
restore EGFR levels, work on the same time scale as negative
feedback mechanisms, and protect the robustness of ligand-
induced mitogenic stimulation31. Our results suggest that
RanBP6 contributes to cellular EGFR homeostasis by con-
stitutively repressing EGFR transcription and being “switched off”
in the setting of increased cellular EGFR demand such as ligand-
induced EGFR degradation (Fig. 7).
EGFR has been reported to localize to the nucleus (for review see
ref. 32,33) through a process that involves trafficking of EGFR from
the plasma membrane to the ER, binding to the Sec61 translocon,
retro-translocation from the ER to the cytoplasm, and association
with importin β13. Once in the nucleus, EGFR has been shown to
act as a transcriptional co-activator for several genes17,34. Our data
is consistent with previous findings that EGFR may serve as a
scaffold to shuttle a fraction of STAT3 molecules toward the
nucleus16,35–37 and that STAT3 molecules enters the nucleus
through an importin-mediated nuclear transport mechanism19. Our
observation that STAT3 is a direct transcriptional repressor of
EGFR, which has not previously been reported, is consistent with
the recent report of increased EGFR signaling following JAK-STAT
inhibition38 and may have implications for strategies to develop
STAT3 inhibitors for cancer therapy. Further studies are needed to
determine how RanBP6-facilitated nuclear transport of STAT3
affects the substantial repertoire of STAT3-associated cellular
functions and dissect transcriptional programs regulated by STAT3
and phosphorylated STAT339–41.
EGFR is one of the first receptor tyrosine kinases linked to human
cancer and represents an important drug target in oncology42.
Aberrant activation of EGFR and other ErbB receptor family
members in cancer is primarily attributed to increased gene copy
numbers or gain-of-function mutations in the genes encoding these
receptors. However, unbalanced ErbB activation in cancer can also
result from defects in EGFR feedback regulation25. ERBB receptor
feedback inhibitor 1 (ERRFI; also known as mitogen-inducible gene
6 protein), e.g., which encodes a cytosolic protein that directly binds
and inhibits ErbB-family receptors, is deleted in cancer and has
shown tumor suppressor activity in experimental cancer models43,44.
Our data suggest that RanBP6 possesses similar tumor suppressor-
like activity, at least in GBM. While RanBP6 did not affect a variety
of cancer-associated signaling molecules, including other receptor
tyrosine kinases (e.g., PDGFRA, PDGFRB, ERBB2, and ERBB3)
(Supplementary Fig. 12), we cannot exclude the possibility that the
tumor suppressor activity of RanBP6 is mediated by effects that go
beyond its effects on EGFR. The nuclear transport machinery is
tightly regulated and can be disrupted in cancer through mutations
or altered expression of nuclear transport components or disruption
of the RanGTP/GDP gradient45,46. Taken together, our data identify
a link between the Ran-GTPase nuclear transport pathway and key
cancer signaling pathways, which warrant further study as inhibitors
targeting nuclear transporters enter clinical evaluation as cancer
therapeutics45,46.
Methods
Cell lines and reagents. Epidermoid carcinoma cell line A431, human embryonic
kidney HEK-293T, DF1, human glioma cell lines LN18, T98G, A172 were pur-
chased from ATCC. SF268 and SF295 were obtained from NCI. SKMG-3 cells were
a gift of Hans Skovgaard (Rigshospitalet, Oslo). HEK-293T and LN18 were
authenticated by SNPs analysis. GBM tumor spheres were derived at the MSKCC
Brain Tumor Center according to MSKCC IRB guidelines. MEF PTENlox/lox were
kindly provided by Hong Wu (UCLA). All the cell lines were routinely checked for
mycoplasma contamination by PCR analysis. DNA fingerprinting was previously
performed for authentication of all glioma cell lines47. Antibodies to RanBP6
(ab74448; 1:1000), EGFR (ab52894; 1:960 for immunofluorescence staining),
RanGAP1 (ab92360; 1:200), and CRM1 (ab24189, 1:1000) were purchased from
Abcam. Antibodies to EGFR (#2085; 1:500 for GST-RanBP6 pulldown and
1:1000–5000 for immunoblot), pEGFR Tyr1068 (#3777; 1:1000), Gab1 (#3232;
1:1000), pGab1 Tyr627 (#3231; 1:1000), pErk1/2 Thr202/Tyr204 (#9101; 1:1000),
Akt (#9272S; 1:1000), pAkt Ser473 (#4051; 1:1000), S6 (#2317S; 1:1000), pS6
Ser240/244 (#5364; 1:1000), PTEN (#9556; 1:1000), STAT3 (# 12640S; 1:1000),
p-STAT3 Tyr705 (#9145S; 1:1000), Ac-STAT3 Lys685 (#2523S; 1:250), H3
(#4499S; 1:5000), p27Kip1 (#2552, 1:500), RB (#9309, 1:1000), and Foxo3a (#2497,
1:1000) were purchased from Cell Signaling. Antibodies to GST (G7781; 1:50,000),
V5 agarose affinity gel (A7345; 6 μl antibody/1 mg lysate), importin α (I1784;
1:1000), importin β (I2534; 1:500), Ran (R4777; 1:1000), Vinculin (V9131;
1:10,000), and β-actin (A2228; 1:50,000) were purchased from Sigma. Antibody to
V5 (P/N 46-1157; 1:5000) is from Invitrogen. Antibodies against Nup93
(SC-374399; 1:500), RCC1 (SC-55559; 1:1000), STAT3 (SC-482; 1:100 for immu-
nofluorescence staining), tubulin (SC-23948; 1:10,000) and survivin (SC-17779;
1:200) were purchased from Santa Cruz. The AKT inhibitor MK2206, XPO1
inhibitor KPT330 (selinexor), and KPT185 were purchased from Selleckchem, and
the JAK inhibitor ruxolitinib (Novartis) was kindly provided by Ross Levine.
RanBP6 expression vectors and knockdown reagents. To generate the RANBP6
expressing lentiviral construct, RanBP6 was PCR amplified using pBluescriptR-
human RanBP6 (Open Biosystems, clone ID 30347107) as template and the pri-
mers pLenti6.3-RanBP6-V5 forward and reverse listed in Supplementary Table 2.
The amplified product was then transferred into a lentiviral expression plasmid
(pLenti6.3/V5-DEST, Invitrogen) with the Gateway recombination technology
using the pDONR221 vector as an intermediate vector. Construct was Sanger
sequence verified. GST-RanBP6 was generated by sub-cloning the amplified PCR
product of human RanBP6 to a digested GST vector (pGEX6.2, GE Healthcare).
TRIPZ RanBP6-inducible shRNAs from Open Biosystem (V3THS_374866 and
V3THS_374867) were used to knockdown human RanBP6. Mouse-specific
RanBP6 hairpin was designed and cloned into the mir30-based retroviral MLP
vector (kindly provided by Scott Lowe) and subsequently into the RCAS vector
(Supplementary Table 3). RanBP6 cDNA that is resistant to the human hairpin
V3THS_374867 was generated by PCR cloning of human RanBP6 cDNA to
MSCV-MIGR1-GFP plasmid (Addgene #27490). Three codons inside the hairpin
sequence were swapped to generate silence mutations by Site-directed Mutagenesis
Kit (Agilent Technologies, catalog #210519-5). TRIPZ STAT3-inducible shRNAs is
from Open Biosystem (V3THS_376017).
Cell line transfections and infections. Adherent lines were grown in DMEM 10%
FBS (Omega scientific, FB-11). Neurospheres were grown in NeuroCult NS-A Pro-
liferation Kit (Stem Cell Technology) supplemented with heparin (2mg/ml), human
EGF and bFGF (20 ng/ml each). Lentivirus and retrovirus were generated by co-
transfection of retro or lentiviral plasmids and the packaging VSVg for retrovirus and
pMD2G and psPAX2 for lentivirus in Gp2-293 using calcium phosphate. High titer
virus was collected at 36 and 60 h following transfection and used to infect cells for
12 h. TS516 was spin-infected for 2 h at 1000 rpm. Transduced cells were selected
after 48 h from the last infection with blastidicin (2–5 μg/ml), G418 (500–800 μg/ml),
and puromycin (3 μg/ml) according to the plasmid antibiotic resistance. DF1 cells
were grown at 39 °C in DMEM (ATCC) containing 10% FBS (Sigma, F7524).
DF1 cells were transfected with the RCAS viral plasmids, using Fugene 6 Trans-
fection reagent (Roche), accordingly to manufacturer’s protocol. EGF time course
experiments were carried out in cells serum starved for 16 h and then stimulated with
100 ng/ml EGF for the indicated time. EGF and Dox were from Sigma.
Immunoprecipitation and immunoblotting. A431 PTEN isogenic-Dox-inducible
RanBP6 V5 cells were induced or not with 1 μg/ml Dox and were lysed 36 h later in
JS lysis buffer (50 mM HPES, 150 mM NaCl, 1% glycerol, 1% Triton X-100, 1.5
mM MgCl2, 5 mM EGTA). Lysates were precleared by incubation for 1 h at 4 °C
with Protein G/A (Calbiochem) blocked in 5% BSA and then incubated with the
V5 antibody (Invitrogen) for 2 h, followed by 1 h incubation with Protein G/A. The
immunoprecipitates were washed four times with JS lysis buffer and bound pro-
teins were eluted in laemmli buffer. Proteins for immunoblot analysis were run
either on 4–12% Bis-Tris SDS–polyacrylamide gel electrophoresis (PAGE) gels
(Invitrogen) or on house-made SDS–PAGE gels and transferred to nitrocellulose
membrane (Amersham). Membranes were incubated in blocking buffer (5% milk,
0.1% Tween, 10 mM Tris at pH 7.6, 100 mM NaCl) and then with primary anti-
body either 1 h at room temperature or overnight at 4 °C according to the antibody.
Anti-mouse or rabbit-HRP-conjugated antibodies (Jackson Immunoresearch) were
used to detect protein by chemiluminescence with ECL (Amersham). Uncropped
scan of the main western blots is reported in Supplementary Figs. 14–16.
GST fusion protein purification and pulldown assay. BL21 cells transformed
with pGEX6p2-RanBP6 were grown in 200 ml of LB medium at 37 °C to an A600 of
0.4–0.7. Protein was induced by culturing in the presence of 1 mM of isopropyl-
thio-D-galactopyranoside (IPTG) at 20 °C for 16 h. Bacterial pellets were collected
by centrifugation at 7700×g for 10 min at 4 °C. Pellets were resuspended in 10 ml of
cold lysis buffer (1% Triton X-100, 1 mM of dithiothritol, 1× protease inhibitor
cocktail I, and 1× phosphatase inhibitor cocktail in 1× PBS). Resuspended bacterial
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lysates were sonicated (41% amplitude, 4 pulses of 10 s/cycle) and centrifuged at
12,000 rpm for 15 min at 4 °C. The supernatants were transferred to 15 ml falcon
tube and incubated with 50% GST beads slurry at 4 °C for 2–4 h. Supernatants with
beads were then sedimented at 500×g at 4 °C for 5 min, and washed twice with ice-
cold wash buffer, and washed again with 1× PBS without detergent. Beads were
finally resuspended in 1–2 bed volumes of GST maintenance buffer (50 mM Tris,
100 mM NaCl 1 mM EDTA, 10% glycerol, 1 mM dithiothritol, and 1× protease and
phosphatase inhibitors). The proteins were aliquoted, snap frozen with liquid
nitrogen, and stored at −80 °C. About 25 μg of GST empty vector and pGEX-
RanBP6 beads were incubated with 500 μg of cell lysates on a rotator in the cold
room for 2–4 h. Lysates from HEK-293T were from cells either serum starved for
12 h and stimulated with EGF (100 ng/ml) or grown in full media. The beads were
sedimented, washed three times with cold lysis buffer (Cell Signaling, catalog
#9803S) with 5 min incubation at 4 °C in between washes, and then lysed with
2× SDS sample buffer (Bio-Rad, #161-0737).
Mass spectrometry. Lysates from A431 cells serum starved for 24 h and stimu-
lated with EGF (100 ng/ml) for 5 min and from A431-Dox-inducible RanBP6-V5
cell serum starved for 24 h were precleared by ultracentrifugation at 45,000 rpm for
45 min. For the immunopurification of EGFR interactors, 4 mg of lysate was
incubated for 2 h and 30 min at 4 °C with 100 μl (slurry 50%) of Cetuximab
antibody conjugated to magnetic Dynabeads protein G (Life Technologies). For the
immunopurification of the RanBP6 interactors, 2 mg of lysates was incubated
overnight with 12 μl anti-V5 agarose affinity gel (Sigma). Supernatants were then
removed and beads were washed six times with lysis buffer. The EGFR complexes
were eluted in two rounds using 500 mM NH4OH and 1mM EDTA in two rounds
of 10 min. The RanBP6–V5 complexes were instead obtained by V5 peptide
(Sigma) elution competition in two rounds of 20 min. Negative controls were
carried along by precipitating proteins with mouse IgG instead of Cetuximab and
with V5 agarose affinity gel in A431 parental cells. Three and four replicates for
EGFR and V5 immunoaffinity, respectively, were performed. Elutions were
resolved using SDS–PAGE, followed by staining with Coomassie blue and excision
of the separated protein bands; in all experiments, prominently stained EGFR band
(Mr ~ 170 kDa) and RanBP6-V5 band (Mr ~ 125 kDa) were always excised as an
individual protein band for analysis. This was done to enhance the dynamic range
encountered during analysis of complex protein mixtures and detection of peptides
arising from proteins found in less abundant amounts compared to EGFR and
RanBP6-V5. In situ trypsin digestion of polypeptides in each gel slice was per-
formed as described48. The tryptic peptides were purified using a 2-µl bed volume
of Poros 50 R2 (Applied Biosystems, CA) reversed-phase beads packed in
Eppendorf gel-loading tips49. The purified peptides were diluted to 0.1% formic
acid and then subjected to nano-liquid chromatography coupled to tandem mass
spectrometry (nanoLC-MS/MS) analysis as follows. Peptide mixtures (in 20 µl)
were loaded onto a trapping guard column (0.3 × 5 mm Acclaim PepMap 100 C18
cartridge from LC Packings, Sunnyvale, CA) using an Eksigent nano MDLC system
(Eksigent Technologies, Inc., Dublin, CA) at a flow rate of 20 µl/min. After
washing, the flow was reversed through the guard column and the peptides eluted
with a 5–45% acetonitrile gradient over 85 min at a flow rate of 200 nl/min, onto
and over a 75-micron × 15-cm fused silica capillary PepMap 100 C18 column (LC
Packings, Sunnyvale, CA). The eluent was directed to a 75-micron- (with
10-micron orifice) fused silica nano-electrospray needle (New Objective, Woburn,
MA). The electrospray ionization needle was set at 1800 V. A linear ion quadrupole
trap-Orbitrap hybrid analyzer (LTQ-Orbitrap, ThermoFisher, San Jose, CA) was
operated in automatic, data-dependent MS/MS acquisition mode with one MS full
scan (450–2000m/z) in the Orbitrap analyzer at 60,000 mass resolution and up to
10 concurrent MS/MS scans in the LTQ for the 10 most intense peaks selected
from each survey scan. Survey scans were acquired in profile mode and MS/MS
scans were acquired in centroid mode. The collision energy was automatically
adjusted in accordance with the experimental mass (m/z) value of the precursor
ions selected for MS/MS. Minimum ion intensity of 2000 counts was required to
trigger an MS/MS spectrum; dynamic exclusion duration was set at 60 s. Initial
protein/peptide identifications from the LC-MS/MS data were performed using the
Mascot search engine (Matrix Science, version 2.3.02; www.matrixscience.com)
with the human segment of Uniprot protein database (20,273 sequences; European
Bioinformatics Institute, Swiss Institute of Bioinformatics and Protein Information
Resource). The search parameters were as follows: (i) two missed cleavage tryptic
sites were allowed; (ii) precursor ion mass tolerance = 10 ppm; (iii) fragment ion
mass tolerance = 0.8 Da; and (iv) variable protein modifications were allowed for
methionine oxidation, cysteine acrylamide derivatization, and protein N-terminal
acetylation. MudPit scoring was typically applied using significance threshold score
p< 0.01. Decoy database search was always activated and, in general, for merged
LS-MS/MS analysis of a gel lane with p< 0.01, false discovery rate averaged around
1%. Scaffold (Proteome Software Inc., Portland, OR), version 4_4_4 was used to
further validate and cross-tabulate the tandem mass spectrometry- (MS/MS) based
peptide and protein identifications. Protein and peptide probability was set at 95%
with a minimum peptide requirement of 1.
Gene ontology analysis. The gene ontology enrichment was performed using the
Gene Ontology Consortium website (www.geneontology.org), through the analysis
tools from the PANTHER Classification System, by uploading the list of the
Uniprot_IDs of the proteins identified in the mass spectrometry experiments. The
enrichment results were filtered to reduce the number of redundant GO classes, by
using the “Clusterprofiler” and “GOSemSim” packages in R [57,58]. All code used to
analyze the data and generate the plots is available at: https://github.com/squatrim/
oldrini2017.
CRISPR/Cas9-mediated knockout of RanBP6. RanBP6 CRISPR constructs were
generated with guided RNAs that target human RanBP6 sequence (Supplementary
Table 3) and pX330 CRISPR/Cas9 vector (Addgene #42230)50. pX330 vector was
digested with BbsI and ligated with annealed oligonucleotides. HEK-293T cells
were transfected with three different sgRanBP6 constructs. Clonal isolations were
performed by serial dilutions (0.5 cells/well). Genomic DNA extractions were
performed with the cell lines that are recovered from single cells. Each of the clones
was examined by SURVEYOR nuclease assays. The PCR products that were
amplified from SURVEYOR primers (Supplementary Table 3) were further vali-
dated by Sanger sequence to confirm the indels. Out of all the clones that were
generated by three independent sgRNAs, we selected the one that has the best
knockout efficiency for further experiments.
Subcellular fractionation assay. Cytoplasmic and nuclear fractions of HEK-293T
cells serum starved for 12 h and treated either with EGF (100 ng/ml) for 15min or
IL-6 (10 ng/ml) for 30min were prepared with Nuclear Extract Kit (Active Motif,
#40010.) The cytoplasmic fractions were extracted with hypotonic buffer. The nuclear
pellets were stringently washed four times before addition of nuclear lysis buffer,
vortexed, and briefly sonicated (10% amplitude for 5 s) before 30min incubation on a
rotator at 4 °C. For subcellular analysis of STAT3, the lysates were normalized to
protein concentration. For GST-RanBP6 pulldown with Ran and RCC1, the frac-
tionated lysates were normalized to the cell number (cytoplasm:nuclear = 50:1).
Reverse transcription quantitative PCR. RNA was isolated with TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. For reverse transcription
PCR (RT-PCR), 500 ng of total RNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA was
used for quantitative PCR using SYBR Green ER Kit (Invitrogen) according to the
manufacturer’s instructions. Quantitative PCRs were run and the melting curves of
the amplified products were used to determine the specificity of the amplification.
The threshold cycle number for the genes analyzed was normalized to GAPDH and
HPRT. Sequences of the primers used are listed in Supplementary Table 4 and
primers for human RANBP6 (PPH13358B), ERBB2 (#PPH00209B-200), and
ERBB3 (#PPH00463B-200) are from Qiagen.
Luciferase assay. The promoter constructs of EGFR and actin (ACTB) were
purchased from SwitchGear Genomics (product ID: #S714178 and #S717678). For
measuring EGFR promoter activity, HEK-293T cells expressing Dox-inducible
shRanBP6 were either treated with or without Dox for 72 h, and were further
serum starved for 16 h. About 50 ng of actin or EGFR promoter construct and 10
ng of cypridina control were co-transfected to the cells with Fugene. The luciferase
activities of renilla and cypridina were measured 48 h after transfection by fol-
lowing the manufacturer’s protocol (LightSwitch Dual Assay System, SwitchGear
Genomics #DA010). STAT3 reporter for measuring the transcriptional activity of
STAT3 was purchased from Qiagen (#CCS-9028L). For STAT3 reporter assay,
both HEK293T and HEK293T-RanBP6 cell lines were treated with or without Dox
for 72 h. Both of the cell lines were transfected with 100 ng of STAT3 reporter
construct. The luciferase assay was developed by using Dual-Glo Luciferase Assay
System from Promega (Catalog #E2920). The cells were seeded at a concentration
of 15,000 cells/well in the 96-well plate, and were transfected at 60–80% confluence.
Each measurement was done in biological triplicates with SpectraMax M5 multi-
mode microplate readers (Molecular Devices).
Gene expression array and ssGSEA. HEK-293T cells expressing Dox-inducible
RanBP6 hairpins were either treated with or without Dox for 72 h, and further
serum starved for 16 h. Total RNA was extracted with Qiagen RNeasy Mini Kit.
The quality of the RNA was evaluated using Agilent BioAnalyzer RNA nano assay,
and the high-quality RNA samples were processed for microarray at the Integrated
Genomics Operation (IGO) at MSKCC. In summary, 500 ng of the RNA was
reverse transcribed to double-stranded cDNA. The cDNA was used as a template
for in vitro transcription with biotin-labeled uridine triphosphate at 37 °C for 16 h.
The biotin-labeled cDNA was fragmented, and processed to hybridization cocktail
to be hybridized to the GeneChip Human Genome U133 Plus 2.0 arrays (Affy-
metrix) according to the Affymetrix GeneChip protocol. Each sample was done in
biological triplicates. Expression array analysis was completed in R (version 3.2.2)
using the Bioconductor suite. The “affy” package was used for robust multi-array
average normalization followed by quantile normalization. For genes with several
probe sets, the median of all probes had been chosen. Data are available online at
NCBI GEO, Accession Number GSE76943. ssGSEA has been performed in R using
the “gsva” function of the “gsva” package. STAT3-related gene lists were down-
loaded from the Molecular Signatures Database (MSigDB) at the Broad institute
(http://software.broadinstitute.org/gsea/msigdb). All code used to analyze the data
and generate the plots is available at: https://github.com/squatrim/oldrini2017.
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Chromatin immunoprecipitation. ChIP was performed as described in Frank
et al.51 LN18 cells were treated with or without Dox and starved overnight with
DMEM without serum. Cells were fixed with 1% formaldehyde for 15 min, stopped
with 0.125 M glycine for 5 min, and washed twice with PBS. Cell pellets were
sonicated for 6 min at 20% amplification (15 s on followed by 60 s off) followed by
2 min sonication at 40% (15 s on followed by 60 s off) with a Branson 450 Sonifier.
Lysates were precleared with Protein A/G beads (Santa Cruz) and incubated at 4 °C
overnight with 5 μg of polyclonal antibody specific for STAT3 (sc-482, Santa Cruz),
or normal rabbit immunoglobulins (Santa Cruz). DNA was eluted in 100 μl of
water and 5 μl was analyzed by qRT-PCR with SYBR Green (Applied Biosystems).
The amplification product was expressed as a percentage of the input for each
condition. The HPRT gene promoter was used as negative control52. Primers used
to amplify sequences surrounding predicted binding sites were designed using the
Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)
based on STAT3-binding site prediction using the Jaspar transcription profile
database (http://jaspar.genereg.net)20 and the MatInspector software (http://www.
genomatix.de).
Immunofluorescence. HEK-293T cells were seeded at 10,000 cells/well on 12 mm
poly-D-lysine and fibronectin-coated rounded coverslip in 24-well plate and cul-
tured in the presence of 2 μg/ml of Dox for 4 days with the last 16–18 h in serum-
starved condition. About 1 μM of ruxolitinib was applied to the culture for 4 h and
10 ng/ml IL-6 for 30 min. Cells were fixed in 3.2% PFA in PBS for 20 min, washed
three times in PBS, incubated for 20 min in blocking solution (10% donkey or goat
serum in 0.1% Triton-X PBS), incubated for 2 h with 1:100 rabbit anti-STAT3
(Santa Cruz, sc-842) in blocking solution, washed three times in PBS, incubated for
1 h with 1:500 anti-rabbit A488 (Invitrogen) in 0.1% Triton-X PBS, washed three
times in PBS, and mounted with Vectashield HM-DAPI (Vector Laboratories, H-
1500). Cultures were imaged with Leica TCS SP5-II microscope and analyzed using
a standardized Metamorph macro. STAT3 signal was first threshold to select the
signal over the background, then the DAPI image was used to subdivide the
threshold STAT3 signal into nuclear and cytoplasmic, and ratio was calculated. For
the staining of human GBM tissue sections, tumors were formalin-fixed, paraffin-
embedded, cut into 5 μm sections, and stained with DAPI (Molecular Probes,
D3571), RanBP6 (polyclonal, ab74448, Abcam; 1:200), and EGFR (clone EP38Y,
ab52894, Abcam; 1:960). Several fields of view were selected by a neuropathologist
for further analysis. Specificity of RanBP6 staining and lack of cross-reactivity for
RanBP5 was determined in normal tissue sections and HEK-293T cells transfected
with cDNA for RanBP6 or RanBP5. Image acquisition, registration, segmentation,
and quantification were performed using the method previously described53.
Soft agar assay. TS516 cells were seeded in triplicates at 300,000 cells/well in
Neurocult media containing 0.4% Noble agar (SIGMA A5431) and growth factor
supplements (20 ng/ml EGF, 10 ng/ml bFGF) and SF268 at 50,000 cells/well in
DMEM 10% FBS. Cells were plated between two layers of Neurocult media and
growth factors or DMEM and FBS containing 0.65% Nobel agar. Noble agar layers
were containing Dox at 1.2 μg/ml. Colonies were stained 3/4 weeks after plating
with either crystal violet (0.005%) (Sigma V5265) and quantified using imagine
software (Oxford Optronix) and an image processing algorithm (Charm algorithm,
Oxford Optronix).
Evaluation of glioma growth in vivo. For the TS516 xenograft model, 4–6 weeks
old female SCID mice were injected subcutaneously with 106 glioma cells, which
were suspended in 100 μl of a 50:50 mixture of growth media and Matrigel (BD
#356237). Mice were then randomly assigned to treatment groups (Dox or control).
Ntv-a mice, and procedures for RCAS-mediated gliomagenesis have been described
previously54. Ntv-a pups were injected with a total of 200,000 DF1 cells transfected
with various constructs: 100,000 RCAS-PDGFB plus 100,000 RCAS-shRanBP6 or
RCAS-shLuc. After injection of the DF1 cells during the newborn period, mice
were aged until they developed symptoms of disease (lethargy, poor grooming,
weight loss, macrocephaly). Samples in panel i of Fig. 6 are derived from tumors
generated in a Ntv-a; Ink4a/Arf null background. RCAS-shRanBP6 and RCAS-
shLuc constructs express a EGFP reporter that allowed to isolate the tumor cells by
FACS. For the derivation of primary cells for FACS analysis, tumors were digested
to a single-cell suspension by 10 min of incubation at 37 °C with 5 ml of papain
digestion solution (0.94 mg/ml papain (Worthington), 0.48 mM EDTA, 0.18 mg/ml
N-acetyl-L-cysteine (Sigma) and 0.06 mg/ml DNase I (Sigma) diluted in Earl’s
Balanced Salt Solution (EBSS). After digestion, the enzyme was inactivated by the
addition of 2 ml of 0.71 mg/ml ovomucoid (Worthington). The cell suspension was
then passed through a 40-μm mesh filter to remove undigested tissue and cen-
trifuged at a low speed (750 r.p.m.) to remove debris and obtain the cell pellet54.
Cells were then resuspended in 500 μl of PBS to be sorted. All animal experiments
were performed according to protocols approved by the Institutional Animal Care
and Use Committee of Memorial Sloan Kettering Cancer Center and CNIO-ISCIII
Ethics Committee for Research and Animal Welfare (CEIyBA) and they were
performed in accordance with the guidelines stated in the International Guiding
Principles for Biomedical Research Involving Animals, developed by the Council
for International Organizations of Medical Sciences (CIOMS).
Statistical analysis. Data are presented throughout as mean and SD, except
otherwise indicated. Results were analyzed by unpaired two-tailed Student’s t tests
unless otherwise noted and were considered statistically significant if p < 0.05.
Kaplan–Meier survival curve was produced with GraphPad Prism; p-value was
generated using the log-rank statistic.
Data availability. The microarray data have been deposited in the NCBI GEO
database under the accession code GSE76943. The proteomic data have been
deposited in the UCSD MassIVE database (https://massive.ucsd.edu/ProteoSAFe/
static/massive.jsp) under MassIVE accession IDs MSV000081631 and
MSV000081632. The CCLE data referenced during the study are available in a
public repository from the cBio Portal55 using the “cgdsr” package. The TCGA
GBM and REMBRANDT data referenced during the study are available in a public
repository from GlioVis data portal (http://gliovis.bioinfo.cnio.es)56. All code used
to analyze the data and generate the plots is available at: https://github.com/
squatrim/oldrini2017. All the other data supporting the findings of this study are
available within the article and its Supplementary Information files, and from the
corresponding authors upon reasonable request.
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